RegenxBio Bets Its Gene Therapy Technology Provides Competitive Edge


 

The U.S. Food and Drug Administration recently granted gene therapy developer RegenxBio Orphan Drug designation for its experimental gene therapy to treat CLN2 disease, a form of Batten disease, a rare and deadly condition that progressively robs children of their abilities until they die. The gene therapy is one of 12 clinical programs and 20 partnered programs RegenxBio is advancing. We spoke to Ken Mills, CEO of RegenxBio, about CLN2 disease, the company’s next-generation gene therapy platform, and why he believes it offers advantages over other AAV gene therapies.

Filed Under: Business, Drug Development, Global Genes, Innovation, RARECast Podcasts, Science & Technology

be-a-guest-blogger

Follow us on Twitter